You are here

  • Home
  • Archive
  • Volume 67, Issue 6
  • Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

Article info

Article menu

Download PDFPDF

XML
Pancreas
Original article
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

Authors

  • Timothy M Nywening Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Brian A Belt Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA Tumor Biology Program, University of Rochester Medical Center, Rochester, New York, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Darren R Cullinan Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Roheena Z Panni Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Booyeon J Han Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA Tumor Biology Program, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Dominic E Sanford Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Ryan C Jacobs Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Jian Ye Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA Tumor Biology Program, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Ankit A Patel Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA Tumor Biology Program, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • William E Gillanders Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Ryan C Fields Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • David G DeNardo Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA Department of Medicine, Oncology Division, Washington University School of Medicine, St. Louis, Missouri, USA Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • William G Hawkins Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Peter Goedegebuure Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • David C Linehan Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA Tumor Biology Program, University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr David C Linehan, University of Rochester Medical Center, Rochester, New York, USA; David_Linehan{at}urmc.rochester.edu
View Full Text

Citation

Nywening TM, Belt BA, Cullinan DR, et al
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma
Gut 2018;67:1112-1123.

Publication history

  • Received January 8, 2017
  • Revised October 9, 2017
  • Accepted October 10, 2017
  • First published December 1, 2017.
Online issue publication 
August 06, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/